This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
JNJ Touches New Highs Post Solid Q4 Earnings: ETFs in Focus
by Sweta Killa
The solid results coupled with upbeat vaccine data optimism pushed JNJ shares to all-time high.
Regeneron (REGN) Reports Positive Data on Cocktail for COVID-19
by Zacks Equity Research
Regeneron (REGN) reports positive initial results from a phase III study evaluating REGEN-COV antibody cocktail as a passive vaccine for the prevention of people at high risk of COVID-19 infection.
Biotech Stock Roundup: Coronavirus Updates From REGN, MRNA, & Other Updates
by Zacks Equity Research
The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Regeneron (REGN), Moderna (MRNA) and Exelixis (EXEL).
The Zacks Analyst Blog Highlights: Moderna, Pfizer, BioNTech and AstraZeneca
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Moderna, Pfizer, BioNTech and AstraZeneca
Can Moderna ETFs Gain on COVID Vaccine Update Against Variants?
by Sweta Jaiswal, FRM
Positive coronavirus vaccine update from Moderna (MRNA) has hogged investors' attention.
How Long Will Coronavirus Vaccine Drive Moderna (MRNA) Stock?
by Zacks Equity Research
Moderna's (MRNA) progress with coronavirus vaccine development and its approval is driving its share prices for the past year. Will the trend continue?
The Zacks Analyst Blog Highlights: NIKE, Amgen, Morgan Stanley, Vertex Pharma and Moderna
by Zacks Equity Research
The Zacks Analyst Blog Highlights: NIKE, Amgen, Morgan Stanley, Vertex Pharma and Moderna
Top Stock Reports for NIKE, Amgen & Morgan Stanley
by Sheraz Mian
Today's Research Daily features new research reports on 12 major stocks, including NIKE (NKE), Amgen (AMGN), and Morgan Stanley (MS).
Pfizer (PFE) to Supply 40M Doses of Coronavirus Vaccine to COVAX
by Zacks Equity Research
Pfizer (PFE) and BioNTech inks an agreement with COVAX to supply up to 40 million doses of their COVID-19 vaccine, BNT162b2.
Markets Await Economic and Earnings Data
by Zacks Equity Research
Markets Await Economic and Earnings Data
Quiet Before the Q4 Earnings Storm
by Mark Vickery
Big Tech reports earnings later this week, with Apple (AAPL) and Tesla (TSLA) among the companies putting out quarterly results. We see the Nasdaq +120 points an hour before the opening bell.
VBI Vaccines (VBIV) Provides Updates on COVID-19 Vaccine
by Zacks Equity Research
VBI Vaccines (VBIV) plans to begin a phase I/II study of monovalent vaccine candidate, VBI-2902, in the first quarter of 2021.
Moderna's (MRNA) Coronavirus Vaccine Study Begins in Japan
by Zacks Equity Research
Moderna's (MRNA) partner Takeda doses the first participant in a phase I/II study with Moderna's coronavirus vaccine candidate, mRNA-1273 in Japan.
Will Sarepta's (SRPT) Overdependence on Exondys 51 Hurt?
by Zacks Equity Research
Sarepta Therapeutics' (SRPT) DMD drug sales are rising and pipeline candidates are progressing well. However, dependence on Exondys 51 for near-term growth is a concern.
Moderna (MRNA) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed the most recent trading day at $125.14, moving +0.1% from the previous trading session.
Gritstone (GRTS) to Begin Coronavirus Vaccine Study, Stock Up
by Zacks Equity Research
Gritstone (GRTS) will develop a second generation vaccine candidate against COVID-19 with the potential for both prolonged protection and potency against spike mutants of the virus. Stock rises.
Grifols (GRFS) to Begin Study on Plasma-Derived COVID-19 Drug
by Zacks Equity Research
Grifols (GRFS) to begin a study in Spain to evaluate a plasma-derived medicine that would provide immediate immunity against COVID-19.
Dr. Reddy's (RDY) to Begin Phase III Study on Sputnik Vaccine
by Zacks Equity Research
Dr. Reddy's (RDY) receives approval from the DCGI to conduct a phase III study on the Sputnik V vaccine for the treatment of COVID-19 in India.
Moderna (MRNA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed at $124.06 in the latest trading session, marking a -0.39% move from the prior day.
Stock Market News for Jan 13, 2021
by Zacks Equity Research
Benchmarks closed in the positive territory on Tuesday as investors remained optimistic on possible fiscal stimulus and vaccine roll out.
Markets Prove Buoyant; KB Home (KNH) Beats Q4 Estimates
by Mark Vickery
KB Home's $1.12 per share was well out in front of the 87 cents in the Zacks consensus, while revenues of $1.19 billion topped the $1.11 billion expected.
A Guide to Biotech ETF Investing Amid the Coronavirus Crisis
by Sweta Jaiswal, FRM
The biotech space had an impressive run on the bourses in 2020 as the coronavirus pandemic triggered a race to roll out vaccine and treatment.
COVID-19 Vaccine Production to Ramp Up
by Zacks Equity Research
COVID-19 Vaccine Production to Ramp Up
Covid-19 Vaccinations Promise to Ramp Up
by Mark Vickery
Guidance for the end of 2020 was to have 20 million Americans with the first half of the two-injection immunization treatment; as of now, only around 9 million Americans have received the first dose.
Moderna (MRNA) Stock Up on Vaccine Pipeline Expansion Plan
by Zacks Equity Research
Moderna (MRNA) plans to initiate clinical studies on new candidates as potential vaccine for seasonal flu, HIV and the Nipah virus.